Impact of attention-deficit/hyperactivity disorder on the patient and family: results from a European survey by Coghill, David et al.
BioMed  Central
Page 1 of 15
(page number not for citation purposes)
Child and Adolescent Psychiatry and 
Mental Health
Open Access Research
Impact of attention-deficit/hyperactivity disorder on the patient 
and family: results from a European survey
David Coghill*1, Cesar Soutullo2, Carlos d'Aubuisson3, Ulrich Preuss4, 
Trygve Lindback5, Maria Silverberg6 and Jan Buitelaar7
Address: 1Centre for Child Health, 19 Dudhope terrace, Dundee, Scotland, DD3 6HH, UK, 2Child and Adolescent Psychiatry Unit, Clínica 
Universitaria, University of Navarra, Pio XII, 36. 31080-Pamplona, Spain, 3Mühlenstrasse 61, 49324 Melle, Germany, 4Universitätsklinik für 
Kinder-undJugendpsychiatrie Psychotherapie Bern, Effingerstrasse 12, CH-3011 Bern, Switzerland, 5Ostadalsveien 58, 0753 Oslo, Norway, 
6överläkare, tf enhetschef, BUP Signal, Observatoriegatan 18, 113 29 Stockholm, Sweden and 7UMC St. Radboud (966), Department of Psychiatry, 
Nijmegen, the Netherlands
Email: David Coghill* - d.r.coghill@dundee.ac.uk; Cesar Soutullo - csoutullo@unav.es; Carlos d'Aubuisson - carlos.cordero-da@t-online.de; 
Ulrich Preuss - ulrich.preuss@kjp.unibe.ch; Trygve Lindback - tlindbac@getmail.no; Maria Silverberg - maria.silverberg-morse@sll.se; 
Jan Buitelaar - J.Buitelaar@psy.umcn.nl
* Corresponding author    
Abstract
Background: Children with attention-deficit/hyperactivity disorder (ADHD) often experience problems with education,
interaction with others and emotional disturbances. Families of ADHD children also suffer a significant burden, in terms of strain
on relationships and reduced work productivity. This parent survey assessed daily life for children with ADHD and their families.
Method: This pan-European survey involved the completion of an on-line questionnaire by parents of children (6–18 years)
with ADHD (ADHD sample) and without ADHD (normative population sample). Parents were questioned about the impact of
their child's ADHD on everyday activities, general behaviour and family relationships.
Results: The ADHD sample comprised 910 parents and the normative population sample 995 parents. 62% of ADHD children
were not currently receiving medication; 15% were receiving 6–8 hour stimulant medication and 23% 12-hour stimulant
medication. Compared with the normative population sample, parents reported that ADHD children consistently displayed
more demanding, noisy, disruptive, disorganised and impulsive behaviour. Significantly more parents reported that ADHD
children experienced challenges throughout the day, from morning until bedtime, compared with the normative population
sample. Parents reported that children with ADHD receiving 12-hour stimulant medication experienced fewer challenges during
early afternoon and late afternoon/early evening than children receiving 6–8 hour stimulant medication; by late evening and
bedtime however, this difference was not apparent. ADHD was reported to impact most significantly on activities such as
homework, family routines and playing with other children. All relationships between ADHD children and others were also
negatively affected, especially those between parent and child (72% of respondents). Parents reported that more children with
ADHD experienced a personal injury in the preceding 12 months, including those requiring the attention of healthcare
professionals. Although 68% of parents were satisfied with their child's current treatment, 35–40% stated that their child's
ADHD symptoms needed to be more effectively treated during the afternoon and evening.
Conclusion: This parent survey highlights the breadth of problems experienced by ADHD children and the impact throughout
the day on both activities and relationships. Therefore, there is a need for treatment approaches that take into account the 24-
hour impact of the disorder and include all-day coverage with effective medication.
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Background
Attention-deficit/hyperactivity disorder (ADHD), which
is estimated to affect 4–12% of school-aged children, is
one of the most common neurobehavioural disorders of
childhood [1]. Although little doubt remains that ADHD
affects both genders, the literature on ADHD in females
remains limited [2]. ADHD is characterised by develop-
mentally inappropriate levels of inattention, hyperactivity
and impulsivity, which often gives rise to serious impair-
ments in academic performance and social adaptive and
behavioural functioning, both inside and outside the
home [3,4]. Although ADHD symptoms have been
shown to change with age (hyperactive and impulsive
behaviour decreases, while inattention increasingly
becomes predominant) [5], studies following children
with ADHD into adolescence and early adulthood indi-
cate that ADHD frequently persists and is associated with
significant psychopathology, school and occupational
failure, family and peer difficulties, emotional problems
and low self-esteem [6-10].
ADHD is associated with an increased risk for accidents
among children [11,12]. Compared to children without
ADHD, children with ADHD were more likely to be
injured as pedestrians (27.6% vs 18.3%, respectively) or
bicyclists (17.1% vs 13.8%; respectively) and to have self-
inflicted injuries (1.3% vs 0.1%; respectively) [11]. They
were also more likely to have sustained injuries to multi-
ple body regions (57.1% vs 43%; respectively), to have
sustained head injuries (53% vs 41%; respectively) and to
have been severely injured (13.5% vs 5.4%; respectively)
[11]. During the past decade, epidemiological studies
have also documented high rates of learning disorders
and cormorbid psychiatric difficulties amongst children
with ADHD, most commonly, oppositional defiant disor-
der and conduct and mood and anxiety disorders [13-15].
As they reach adolescence, children with ADHD are also at
an increased risk for cigarette smoking and substance
abuse [16-18]. Furthermore, a comparison between an
ADHD sample of 239 consecutively referred adults with a
clinical diagnosis of childhood-onset and persistent
ADHD, and 268 non-ADHD adults, reported that subjects
with ADHD were significantly more likely to make the
transition from an alcohol-use disorder to a drug-use dis-
order (hazard ratio = 3.8) and were significantly more
likely to continue to abuse substances following a period
of dependence (hazard ratio = 4.9) [16].
Whilst debilitating for the child, ADHD has also been
shown to adversely impact on parents' quality of life, plac-
ing a substantial burden on the family as a whole. Indeed,
families of children with ADHD have been consistently
shown to experience more difficulties than families of
nondisabled controls [9,19]. These include disturbed
interpersonal relationships, particularly less perceived
family cohesiveness and greater conflict, depression in
parents and higher incidences of divorce and separation
[19]. In addition, childhood ADHD has been shown to
adversely affect the child's parents' work status and work
productivity. In a telephone survey of 154 caregivers of
children diagnosed with ADHD, 63% of caregivers
reported some change in their work status as a result of
their child's ADHD. Of these, 15% changed their type of
job, 46% reduced the number of hours worked per week
and 11% stopped work completely [20]. In addition, dur-
ing the 4 weeks prior to the survey, caregivers reported
having lost an average of 0.8 days from work and being
25% less productive, for an average of 2.4 days, due to
their child's ADHD [20].
Although the financial burden of ADHD has not been
fully evaluated, it has been demonstrated that individuals
with ADHD exhibit increased use of mental health, social
and special education services [21,22]. Results from a
population-based cohort study that compared medical
care use and costs amongst 4880 children and adolescents
with and without ADHD over a 9-year period, reported
that the proportion requiring hospital inpatient, hospital
outpatient or emergency department admission was
higher for those with ADHD versus those without ADHD
(26% vs 18% [p < 0.001], 41% vs 33% [p = 0.006] and
81% vs 74% [p = 0.005], respectively). In addition,
median costs for all episodes of care during the 9 years of
follow-up for persons with ADHD were more than double
those of persons without ADHD ($4306 vs $1944, respec-
tively; p < 0.001) [23].
The optimal management of ADHD aims to minimise not
only the core symptoms, but also the associated impair-
ments. Current practice suggests that children with ADHD
benefit from medications such as stimulants (methylphe-
nidate [MPH] and amfetamines) or the non-stimulant
atomoxetine (Strattera®) [24,25], and that effective treat-
ment requires a comprehensive multimodal approach
that includes behaviour modification for many children
[26]. MPH is the best-studied stimulant medication for
ADHD, with results from a number of studies demonstrat-
ing that it significantly improves behavioural and atten-
tion-related symptoms of ADHD and academic and social
functioning [27-32], as well as reducing sequelae such as
the development of psychiatric disorders [32] and sub-
stance abuse [33]. The selective norepinephrine reuptake
inhibitor, atomoxetine, has been shown to be effective in
relapse prevention, with a suggestion that it may also have
a positive effect on global functioning, specifically health-
related quality of life, self-esteem and social and family
functioning [34-36]. To date, much current research in
ADHD has been focused on the objective management of
symptoms, while the effect of the disorder on the everydayChild and Adolescent Psychiatry and Mental Health 2008, 2:31 http://www.capmh.com/content/2/1/31
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functioning and well-being of children with ADHD (e.g.
the ability to undertake homework, participate in after-
school activities and engage with friends and family)
remains relatively unexplored [1]. To address this, a Euro-
pean parent survey was undertaken to examine the impact
of ADHD on their children's everyday activities, general
behaviour and family relationships, as assessed by par-
ents. A secondary aim of the survey was to investigate the
parental assessment of the effect of stimulant medication
on the behaviours of their children with ADHD. This part
of the survey was designed to have a particular focus on
the early morning, afternoon and early evening period as
this is the time when parents have the closest contact with
their children.
Methods
Survey development and description
An on-line, parent-completed questionnaire was designed
with input from both experts in the field of child psychia-
try and paediatrics and experienced ADHD advocates. The
primary aim of the survey was to examine the experiences
of parents with a child with ADHD and the degree to
which their child's ADHD impacts on both the daily life
of the individual child and the family as a whole.
The survey was also designed to explore the differences in
behaviour between children with ADHD receiving stable
medication (> 3 months), children with ADHD not on
medication and children without ADHD. As such, this
questionnaire was completed by a sample of parents with
children with ADHD and a general population sample of
parents with children without ADHD (normative popula-
tion). Parents of children with ADHD were questioned
about the impact of their child's ADHD in three key areas:
(i) everyday activities both 'in the home' (e.g. mealtimes
and homework) and 'outside the home' (e.g. leisure and
family activities); (ii) general behaviour (noisy or disrup-
tive, aggressive or defiant, and impulsive or risk-taking
behaviour); and (iii) family relationships (e.g. the rela-
tionships between the child with ADHD and their par-
ents, siblings, peers and other adults). Similarly, parents
in the normative population sample were questioned
about their non-ADHD child's general behaviour and
their behaviour in relation to everyday activities and fam-
ily relationships.
All questions contained in the survey were multiple
choice and answered using a 7-point scale. This survey
also addressed the times of day at which the children were
perceived by their parents to be affected by their ADHD
(Table 1). On average, the time taken for parents of chil-
dren with ADHD to complete the survey was 10 minutes;
parents with non-ADHD children in the normative popu-
lation sample took approximately 8 minutes to complete
the survey.
Overall, parents from ten European countries (Belgium,
France, Germany, The Netherlands, Norway, Poland,
Spain, Sweden, Switzerland and the United Kingdom)
were invited to participate in the survey. This survey was
sponsored by Janssen Cilag and conducted by Harris
Interactive, an experienced market research company. The
survey was conducted in accordance with guidelines set by
the European Pharmaceutical Market Research Associa-
tions and the Market Research Society.
Sampling strategy
Parents of children with ADHD were drawn from an inde-
pendently sourced sample via third party sample provid-
ers, who had identified households within their panel
(which comprised a total of 1.2 million households in
Europe) where one or more of the children in the house-
hold had ADHD (approximately 114,000 children across
Europe). To supplement this sample group, additional
respondents within the sample providers' panel were also
invited to participate in a screening questionnaire. Parents
of children with ADHD were surveyed between 1st March
to 11th April, 2007.
A sample of parents with children without ADHD were
drawn from the Harris pan European panel, which com-
prised of approximately 3 million households across
Europe, and was representative of the general population
within Europe in terms of age, gender and socio-economic
status. Parents of children without ADHD were surveyed
between 4th June to 21st June, 2007.
Both the ADHD and normative population surveys were
conducted on-line and potential respondents were
screened on a number of selection criteria. For the ADHD
survey, parents were required to have a child (or children)
Table 1: Times of day (including estimated start times) that the effects of ADHD were assessed
Period of the day Median start time
Morning routine (waking up, getting ready for school) 07:00
Morning (school lessons) 08:00
Lunchtime 12:00
Early afternoon (lessons, homework and playtime) 14:00
Late afternoon/early evening 17:00
Late evening 20:00
Bedtime 21:00Child and Adolescent Psychiatry and Mental Health 2008, 2:31 http://www.capmh.com/content/2/1/31
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aged 6–18 years, with a confirmed diagnosis of ADHD
that had been made by a designated healthcare profes-
sional. Parents also had to live in the same household as
the child with ADHD. Due to the fact that atomoxetine
has a substantially different mechanism of action from
stimulant medications, parents whose child with ADHD
received atomoxetine were excluded from participating in
the ADHD survey. In addition, given that one of the objec-
tives of this survey was to investigate the impact of stimu-
lant medication on afternoon behaviours, parents whose
child with ADHD only received a once-daily dose of an
immediate-release stimulant medication, were also
excluded from the ADHD survey. In those instances where
parents had more than one child with ADHD, parents
answered questions with reference to their eldest child
with ADHD. For the normative population survey,
respondents also had to have a child (or children) aged 6–
18 years and had to live with the child (or children). For
parents with more than one child, the survey was com-
pleted with reference to the eldest child. In both surveys
(ADHD and normative population surveys), data was col-
lected and analysed for young (6–10 years) and older chil-
dren (11–18 years). Gender was not considered as a
specific issue during the design of the survey and as such
gender was not controlled for in either the ADHD or the
normative population survey samples.
Overall, invitations to participate in the survey were sent
to 122 069 parents (104,018 parents with a child with
ADHD and 18,051 parents without a child with ADHD),
after which 25,280 parents were enrolled to the screening
questionnaire. Following completion of the screening
questionnaire, 910 parents were enrolled in the ADHD
survey and 995 parents in the normative population sur-
vey (Figure 1)
Statistical analysis
Data collected during the survey was analysed using para-
metric (t-test) or non-parametric (chi-square) tests as
appropriate, carried out at the 5% significance level. Win-
cross (version 7.0) was used for this analysis. Data was
analysed separately for the two groups (ADHD survey par-
ent sample and normative population parent sample).
Results
Sample characteristics
Responses to the surveys were received from 1905 parents
(ADHD parent sample, n = 910; normative population
parent sample, n = 995) (Figure 1). The demographic and
baseline characteristics of the responding parents and
their children are provided in Table 2. The questionnaires
were predominantly completed by mothers. As in most
studies of ADHD, there was a strong male preponderance,
Flow chart of survey design Figure 1
Flow chart of survey design. ADHD = attention-deficit/hyperactivity disorder.Child and Adolescent Psychiatry and Mental Health 2008, 2:31 http://www.capmh.com/content/2/1/31
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with the majority of children described in the survey being
boys (76% in both survey groups). Although it has been
suggested that children with ADHD are over-treated, a
large majority of children with ADHD in this survey
(62%) were not currently receiving medication.
Figure 2 profiles the types of behaviour exhibited by the
children as observed and described by their parents in the
survey. Compared with the normative population sample,
children in the ADHD sample consistently displayed
more exaggerated behaviour as assessed by their parents.
With regards to the ADHD sample, an analysis of younger
(6–10 years) versus older (11–18 years) children, revealed
few differences on the impact of ADHD on everyday activ-
ities, general behaviour and family relationships as
recorded by parents. Therefore, data is presented here for
the entire ADHD age sample (6–18 years).
Times of day that children with attention-deficit/
hyperactivity disorder find challenging
Overall, parents reported that their children with ADHD
find the whole day challenging. An analysis of parent's
responses revealed that a reasonably high percentage of
children with ADHD and children without ADHD experi-
enced challenges with the morning routine (43% vs 41%,
respectively; p = ns). However, over the course of the day,
parents reported that children with ADHD consistently
experienced greater challenges as observed during the
morning (43% vs 12%, respectively; p < 0.05), at lunch-
time (17% vs 3%, respectively; p < 0.05), during the early
afternoon (50% vs 12%, respectively; p < 0.05), late after-
noon/early evening (43% vs 12%, respectively; p < 0.05),
late evening (33% vs 8%, respectively; p < 0.05) and at
bedtime (38% vs 22%, respectively; p < 0.05).
When results were analysed for medicated versus non-
medicated children with ADHD, a significantly higher
Table 2: Clinical characteristics of the ADHD and normative survey population
Characteristics ADHD children (n = 910)* Normative children (n = 995)†
Responding parent
Female, n (%) 716 (79) 612 (61)
Male, n (%) 194 (21) 384 (39)
Age of the majority of respondents, years 38–47 40–44
Marital status of respondents
Single/never married/widowed, n (%) 92 (10) 88 (9)
Married/cohabiting, n (%) 655 (72) 780 (78)
Divorced/separated, n (%) 160 (18) 128 (13)
Number of children aged 6–18 years per household
1 child, n (%) 321 (35) 520 (52)
2 children, n (%) 375 (41) 333 (34)
>/= 3 children, n (%) 214 (24) 142 (14)
Number of children with ADHD per household
1 child, n (%) 430 (73) N/A
> 1 child, n (%) 159 (27) N/A
Gender of child
Male, n (%) 688 (76) 760 (76)
Female, n (%) 222 (24) 235 (24)
Mean age of child, years 11.4 12.0
Average age of ADHD diagnosis, years 6.4 N/A
Medication status for child with ADHD
Receiving stimulant medication, n (%) 350 (38) N/A
6–8 hour medication 140 (40) N/A
12-hour medication 210 (60) N/A
Not receiving medication, n (%) 560 (62) N/A
Length of time ADHD medication prescribed
3–6 months, n (%) 27 (8) N/A
6–12 months, n (%) 52 (15)
> 1 year, n (%) 271 (77)
6–8 hour mediation consisted of long-acting medication taken once-daily or short short-acting medication taken twice-daily; 12-hour stimulant 
medication consisted of long-acting medication taken once-daily, short-acting medication taken three-times daily or a combination of long- and 
short-acting medication
*If > 1 ADHD child with ADHD in household, the survey was completed with reference to the eldest child
†If > 1 child without ADHD in household, survey was also completed with reference to the eldest child
ADHD = attention-deficit/hyperactivity disorder; N/A = not applicableChild and Adolescent Psychiatry and Mental Health 2008, 2:31 http://www.capmh.com/content/2/1/31
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percentage of children receiving stimulant medication
experienced challenges with the morning routine com-
pared with non-medicated children (55% vs 36%, respec-
tively; p < 0.05). With the exception of the early afternoon
period, where a greater percentage of non-medicated chil-
dren experienced challenges compared with medicated
children (53% vs 45%, respectively; p < 0.05), few other
differences were observed by parents between the medi-
cated and non-medicated ADHD groups during the
course of the day.
For medicated children with ADHD, parents reported that
those receiving 12-hour stimulant medication experi-
enced greater challenges with the morning routine than
those receiving 6–8 hour stimulant medication. However,
as the day progressed, children receiving 12-hour stimu-
lant medication experienced less challenges than children
receiving 6–8 hour stimulant medication, although par-
ents noted a trend for children receiving 12-hour stimu-
lant medication to exhibit more challenging behaviour in
the late evening and at bedtime (Figure 3).
Everyday activities reported as challenging in children with 
attention-deficit/hyperactivity disorder
As part of this survey, parents were asked whether, on an
average week day, their child's ADHD affected various
everyday activities: meal-times, homework, playing alone,
playing with other children, following family routines,
individual leisure activities and group leisure activities.
Overall, parents reported that ADHD is adjudged to
impact negatively on all measured activities. In particular,
compared with the normative population sample, a sig-
nificantly higher percentage of children with ADHD were
described as being considerably more challenged in the
areas of homework (74% vs 28%, respectively; p < 0.05),
following family routines (68% vs 28%, respectively; p <
0.05) and playing with other children (52% vs 13%,
respectively; p < 0.05). When questioned at which times
during the course of the day (lunchtime to late evening)
these three activities were most affected in children with
ADHD, parents reported that homework and playing with
other children were most affected during the early after-
noon and late afternoon/early evening, whilst following
family routines was most affected during the late after-
noon/early evening and late evening periods (Figure 4).
Types of behaviour exhibited by children with ADHD compared to children without ADHD Figure 2
Types of behaviour exhibited by children with ADHD compared to children without ADHD. Baseline: all qualified 
respondents (ADHD survey, n = 910; normative population survey, n = 995). *p = 0.0001, non-medicated children with ADHD 
versus children without ADHD. †p = 0.0001, children without ADHD versus non-medicated children with ADHD.Child and Adolescent Psychiatry and Mental Health 2008, 2:31 http://www.capmh.com/content/2/1/31
Page 7 of 15
(page number not for citation purposes)
For children with ADHD, parental assessment on the
impact of behaviour on everyday activities was found to
be similar for both the medicated and non-medicated
groups with a significant difference only being found for
"playing with other children" (56% medicated vs. 49%
non-medicated; p < 0.05). With regards to the times of day
that homework and the following of family routines were
most affected, a similar pattern emerged for both medi-
cated and non-medicated children with ADHD, with par-
ents reporting that both activities were most affected
during the early afternoon and late afternoon/early
evening periods. Playing with other children was reported
by parents as being most affected during the early after-
noon and late afternoon/early evening period. However,
compared with non-medicated children with ADHD, a
higher percentage of medicated children with ADHD
experienced problems in the late afternoon/early evening
periods as assessed by their parents (41% versus 31%,
respectively; p < 0.05).
Relationships affected in families with a child with 
attention-deficit/hyperactivity disorder
Overall, parents reported that ADHD impacted negatively
on all relationships asked about: child-parent, parent-par-
ent, child-sibling(s), child-other children and child-other
adults. However, compared with the normative popula-
tion sample, parents in the ADHD sample reported that
the three relationships that were most affected were those
between the child and parent (72% vs 43%, respectively;
p < 0.05), the child and their sibling(s) (64% vs 29%,
respectively; p < 0.05) and the child and other children
(54% vs 12%, respectively; p < 0.05). When questioned at
which times during the course of the day (lunchtime to
bedtime) these three relationships were most affected,
parents reported that they were affected over the whole
time period assessed. Compared with the normative pop-
ulation sample, parents in the ADHD sample described
the child-parent relationship as being most affected dur-
ing the late afternoon/early evening (50% vs 24%, respec-
tively; p < 0.05) and late evening periods (50% vs 21%,
respectively; p < 0.05). Likewise, compared with the nor-
mative population sample, the child-sibling(s) relation-
ship was also described by parents as being most affected
in the late afternoon/early evening (52% vs 21%, respec-
tively; p < 0.05) and late evening (41% vs 12%, respec-
tively; p < 0.05) periods. Finally, compared with the
normative population sample, the child-other children
relationship was described by parents as being most
affected in the early afternoon (41% vs 9%, respectively; p
< 0.05) and late afternoon/early evening (38% vs 8%,
respectively; p < 0.05) periods.
For children with ADHD, there was no effect of medica-
tion status on the relationships assessed, with parents
Times of the day children with ADHD find challenging compared to children without ADHD Figure 3
Times of the day children with ADHD find challenging compared to children without ADHD. Baseline: all quali-
fied respondents (ADHD survey, n = 910; normative population survey, n = 995). ADHD = attention-deficit/hyperactivity dis-
order. *p < 0.05, non-medicated children with ADHD versus children without ADHD. †p < 0.05, non-medicated children with 
ADHD versus 6–8 hours stimulant medication. ‡p < 0.05, non-medicated children with ADHD versus 12-hour stimulant medi-
cation. §p < 0.05, 6–8 hour stimulant medication versus children without ADHD. ¶p < 0.05, 6–8 hour stimulant medication ver-
sus non-medicated children with ADHD. **p < 0.05, 6–8 hour stimulant medication versus 12-hour stimulant medication. ††p < 
0.05, 12-hour stimulant medication versus children without ADHD. ‡‡p < 0.05, 12-hour stimulant medication versus non-med-
icated children with ADHD. §§p < 0.05, 12-hour stimulant medication versus 6–8 hour stimulant medication.Child and Adolescent Psychiatry and Mental Health 2008, 2:31 http://www.capmh.com/content/2/1/31
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Times of day activities are affected in children with ADHD compared to children without ADHD Figure 4
Times of day activities are affected in children with ADHD compared to children without ADHD. Baseline: all 
qualified respondents (ADHD survey, n = 910; normative population survey, n = 995). *p < 0.05, non-medicated children with 
ADHD versus children without ADHD. †p < 0.05, children without ADHD versus non-medicated children with ADHD. 
ADHD = attention-deficit/hyperactivity disorder.Child and Adolescent Psychiatry and Mental Health 2008, 2:31 http://www.capmh.com/content/2/1/31
Page 9 of 15
(page number not for citation purposes)
reporting that the relationships between the child and
parent, the child and their sibling(s) and the child and
other children were similarly affected amongst medicated
(73%, 67% and 57%, respectively) and non-medicated
children with ADHD (71%, 62% and 52%, respectively).
From lunchtime to early evening, there were no signifi-
cant differences between medicated and non-medicated
children with ADHD, in terms of the impact of their
behaviour on the child-parent or child-sibling(s) relation-
ship. However, compared with non-medicated children
with ADHD, parents reported that a higher percentage of
medicated children with ADHD experienced behavior
that affected the relationship with their parents during the
late evening (54% vs 47%, respectively; p < 0.05) and at
bedtime (49% vs 40%, respectively; p < 0.05). Likewise,
parents reported that the percentage of children with
ADHD whose behaviour affected the relationship with
their sibling(s) was significantly higher in the group
receiving medication at bedtime (34% vs 27%, respec-
tively; p < 0.05). Over the course of the day, no significant
differences were reported by parents between medicated
and non-medicated children with ADHD with regards to
the impact of their behaviour on their relationships with
other children.
Different types of behaviours exhibited by children with 
attention-deficit/hyperactivity disorder
When questioned about the types of behaviour displayed
by their children with ADHD, parents reported a range of
typical ADHD-related behaviours in their children (Figure
2). In particular, compared with the normative popula-
tion sample, parents reported that children with ADHD
displayed more noisy and disruptive behaviour (68% vs
21%, respectively; p = 0.0001), more disorganised behav-
iour (66% vs 38%, respectively; p = 0.0001) and more
excessively demanding and attention seeking behaviour
(69% vs 19%, respectively; p = 0.0001). When questioned
at which times during the course of the day (lunchtime to
late evening) such behaviours occurred in children with
ADHD, a consistent pattern emerged, with parents report-
ing that such behaviours peaked during the late after-
noon/early evening period, receding slightly during the
late evening and at bedtime. A similar trend was also
reported by parents in the normative population sample
(Figure 5).
When results were analysed for medicated versus non-
medicated children with ADHD, medication status did
not significantly alter the proportion of children who
exhibited typical ADHD-related behaviours. According to
parental assessments, the percentage of children with
ADHD reported to display noisy and disruptive behav-
iour, disorganised behaviour and excessively demanding
and attention-seeking behaviour were comparable
between the medicated (69%, 67% and 71%, respec-
tively) and non-medicated groups (68%, 65% and 68%,
respectively). With regards to the times of day that such
behaviours occurred, parents reported that noisy or dis-
ruptive behaviour was displayed by similar proportions of
medicated and non-medicated children with ADHD
throughout the day, except at bedtime, when this was sig-
nificantly more frequent in medicated children (39% vs
31%, respectively; p < 0.05). No significant differences in
disorganised behaviour were reported by parents between
medicated and non-medicated children with ADHD dur-
ing the early afternoon, late afternoon and late evening
periods; however, parents reported that disorganised
behaviour was significantly more frequent in medicated
children with ADHD at lunchtime (44% vs 36%, respec-
tively; p < 0.05) and at bedtime (37% vs 28%, respec-
tively; p < 0.05). Excessively demanding or attention-
seeking behaviour was recorded by parents in a similar
percentage of medicated and non-medicated children
with ADHD over the course of the day.
Number of personal injuries suffered by children with 
attention-deficit/hyperactivity disorder
Parents were also questioned about the number of per-
sonal injuries experienced by their children with ADHD.
Compared with the normative population sample, par-
ents reported that a significantly greater percentage of
children in the ADHD sample (43% vs 28%, respectively;
p < 0.05) experienced a personal injury in the last 12
months. In addition, an analysis of parent's responses
suggest that children with ADHD experience a greater
number of injuries that required the attention of a pri-
mary care physician or paramedic (1.5 vs 1.0, respectively;
p < 0.05) and a visit to hospital (0.8 vs 0.6, respectively; p
< 0.05).
Medication status, as assessed by parents with an ADHD
child, did not have a great impact on the number of inju-
ries. Overall, there were no significant differences between
medicated and non-medicated children with respect to
percentage of medicated children with ADHD experienc-
ing a personal injury in the last 12 months (39% vs 46%,
respectively; p = ns), average number of total injuries
(7.38 vs 6.87, respectively; p = ns), injuries that required
the attention of a primary care physician or paramedic
(1.60 vs 1.47, respectively; p = ns), injuries that required a
visit to the hospital (0.77 vs 0.86, respectively; p = ns) or
injuries that required a stay in hospital (0.17 vs. 0.17,
respectively; p = ns). However when results for the injuries
that required a stay in hospital were analysed separately
for those receiving 6–8 and 12-hour stimulant medica-
tion, parents reported that children receiving 12-hour
medication had significantly less injuries than those
receiving 6–8 hour medication (0.1 vs. 0.27, respectively;
p < .05)(Figure 6)Child and Adolescent Psychiatry and Mental Health 2008, 2:31 http://www.capmh.com/content/2/1/31
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Times of day certain behaviours are exhibited by ADHD children compared to children without ADHD Figure 5
Times of day certain behaviours are exhibited by ADHD children compared to children without ADHD. Base-
line: all qualified respondents (ADHD survey, n = 910; normative population survey, n = 995). *p < 0.05, non-medicated chil-
dren with ADHD versus children without ADHD. †p < 0.05, children without ADHD versus non-medicated children with 
ADHD. ADHD = attention-deficit/hyperactivity disorder.Child and Adolescent Psychiatry and Mental Health 2008, 2:31 http://www.capmh.com/content/2/1/31
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Parents' attitudes towards medication for attention-
deficit/hyperactivity disorder
Overall, the majority of children with ADHD (n = 562
[62%]) were not receiving medication at the time of this
survey (Table 2). When questioned about the times of day
(lunchtime to bedtime) when it was important for their
child's ADHD symptoms to be medicated, 74% of parents
felt that symptoms should be medicated in the early after-
noon. In addition, 55% of parents also felt that it was
important for symptoms to be medicated at lunchtime,
while 54% also reported a need for medication during the
late afternoon/early evening period.
Parents with an ADHD child treated with stimulant med-
ication were also questioned about how satisfied they
were with their child's current ADHD medication, using a
7-point scale ranging from 1 ('not at all satisfied') to 7
('extremely satisfied').
Overall, parents were 'reasonably satisfied' with their
child's medication, with 68% of parents recording a score
of 5, 6 or 7 on this scale. When results were analysed for
children receiving 6–8 hour stimulant medication and 12-
hour stimulant medication, 71% of parents reported that
they were reasonably satisfied with their child's 6–8 hour
stimulant medication and 63% were 'reasonably satisfied'
with their child's 12-hour stimulant medication, as
recorded by a score of 5, 6 or 7 on this scale. Only 4% of
parents (3% of parents whose ADHD child was receiving
6–8 hour stimulant medication and 5% of parents whose
ADHD child was receiving 12-hour stimulant medica-
tion) recorded a score of 1, indicating that they were 'not
at all satisfied' with the ADHD medication their child was
receiving.
As part of this survey, parents with an ADHD child treated
with stimulant medication were also asked whether there
were any particular times of the day (lunchtime to late
evening) when they felt that their child's symptoms
needed to be better controlled. Overall, 47% of parents
felt that their child's symptoms needed to be better medi-
cated in the early afternoon. An additional 41% of parents
felt that there was a need for improved medication in the
late afternoon/early evening period, whilst 37% also
reported a need for more effective medication during the
late evening period.
Discussion
Results from this large European parent survey demon-
strate that parents report that ADHD has a significant
impact on the child and their family, affecting school
work, peer relationships and family relationships. Impor-
Mean number of personal injuries in children with and without ADHD over the last 12 months Figure 6
Mean number of personal injuries in children with and without ADHD over the last 12 months. Baseline: all qual-
ified respondents (ADHD survey, n = 910; normative population survey, n = 995). *p < 0.05, 12-hour stimulant medication ver-
sus 6–8 hour stimulant medication.**p < 0.05, 6–8 hour stimulant medication versus children without ADHD. †p < 0.05, 6–8 
hour stimulant medication versus children without ADHD. †† p < 0.05, non-medicated children with ADHD versus children 
without ADHD. §p < 0.05, non-medicated children with ADHD versus children without ADHD.Child and Adolescent Psychiatry and Mental Health 2008, 2:31 http://www.capmh.com/content/2/1/31
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tantly, parental assessment in this survey clearly high-
lights that all times of the day are challenging for children
with ADHD, with the afternoon/evening period at least as
problematic as the school day. Of note, parents reported
that typical behaviours associated with ADHD (exces-
sively demanding/attention-seeking, noisy/disruptive and
aggressive/defiant behaviour) consistently peaked during
the late afternoon/early evening period. In line with this
finding, a range of everyday activities (homework, playing
with other children and following family routines) and a
number of important relationships (child-parent, child-
sibling and child-other children) were also reported by
parents to be affected during the course of the afternoon
and evening.
Of note, the majority of children with ADHD in this sur-
vey (62%) were not currently receiving medication. This
may be due in part to a European tradition that medica-
tion treatments for ADHD should be reserved for those
with more severe symptoms and impairments. This may
also be related to a number of concerns that have arisen
regarding the use of stimulant medication for children
with ADHD, especially in younger children. These range
from ethical objections to utilising medication to modify
children's behaviour [37] to concerns about the lack of
evidence for the long-term effectiveness of stimulant med-
ication [38]. In addition, many ADHD children who were
receiving pharmacotherapy in this survey continued to
experience significant challenges over the course of a
given day. Although medication status in children with
ADHD was shown to have a positive impact on the
number of personal injuries experienced in the last 12
months, parents reported that the proportion of children
exhibiting typical ADHD-related behaviours and the
impact of such behaviours on everyday activities were
comparable between medicated and non-medicated chil-
dren. Similarly, parents reported there was no apparent
effect of medication on the relationships assessed, with
relationships between the child and their parent, sib-
ling(s) and other children equally affected amongst med-
icated and non-medicated children with ADHD. This may
be due in part to individualised treatment plans for chil-
dren with ADHD [39] and the successful implementation
of a range of evidence-based psychosocial-intervention
alternatives or adjuncts to pharmacological treatment
such as educational interventions, intensive summer
treatment programs, structure/routine and cognitive-
behavioural therapy, social skills training and behavioural
parent training [40-43]. Although results from a number
of studies, including the Multi-modal Treatment Study of
ADHD (MTA Study), have reported that medication man-
agement significantly improves ADHD symptoms [32],
the applicability of these findings beyond the research set-
tings into routine clinical practice remains less clear.
Indeed, it has been suggested that in routine clinical care,
where less intensive monitoring is available, many chil-
dren with ADHD will not receive the maximum benefit
from their medication [32]. This may account for the find-
ing in this parent survey that many children with ADHD
continued to experience challenges despite receiving pre-
scribed medication for their ADHD. Another important
consideration is the fact that these results are based on an
observational study, in which allocation to treatment (i.e
medication versus no medication) was not subject to
experimental procedures such as randomisation. As such,
the decision to prescribe medication will most likely have
been made on the basis of clinician and parent judgment
of the severity of ADHD symptoms and their associated
impairment on functioning. Consequently, the most
severely ill and impaired children with ADHD are likely to
have been offered medication, a factor that may have
resulted in the similarity of results between medicated and
non-medicated children in this survey.
Although there is a misconception that ADHD is a condi-
tion that primarily affects children whilst at school (e.g.
their school grades), which results in some physicians
focusing solely on the impact of ADHD on school activi-
ties, results from this parent survey highlight the impor-
tance of treatment throughout the full active day. Indeed,
when questioned directly, approximately half of parents
reported the need for a medication that extends into the
early afternoon and late afternoon/early evening periods.
Moreover, the observation by parents that there was a
trend for children with ADHD receiving 12-hour stimu-
lant medication to experience more challenges during the
morning routine, in the late evening and at bedtime may
reflect that these children are those with the most severe
ADHD, with pronounced disturbances late in the day,
whose symptoms require medication coverage over the
full course of the active day. However, it is important to
note that individual treatment plans for children with
ADHD may take into account not only the severity of
symptoms and the ensuing daily challenges, but also the
context (e.g. consequences and settings) of symptoms and
the impact of these symptoms on daily functioning.
Indeed, it has been suggested that the primary focus of
assessment of ADHD should be on functional behav-
ioural assessments of impairment such as identifying
impaired domains of functioning, operationalizing target
behaviours within these domains and implementing
treatment measures such as Individualised Target Behav-
iour Evaluation. Such assessments will identify environ-
mental contexts and socially valid target behaviours (not
DSM-IV symptoms of ADHD) and facilitate treatment
planning [39].
Interestingly, although specific parent enquiry demon-
strated a significant degree of challenging behaviours,
many parents who participated in this survey reported rea-Child and Adolescent Psychiatry and Mental Health 2008, 2:31 http://www.capmh.com/content/2/1/31
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sonable satisfaction with their child's current ADHD treat-
ment. These results highlight that, by asking about specific
activities at different times of the day, physicians may be
able to elicit better information from parents that may
guide individual medication decisions and optimize treat-
ment across the day.
Given the importance of considering the treatment of
ADHD symptoms outside of the school environment,
there has recently been great interest in the use of longer
acting stimulant preparations. Current international
guidelines for the management of ADHD recommend the
use of long-acting formulations to reduce the need for in-
school dosage and the likelihood of diversion [44]. To
date, a number of long-acting MPH formulations that
allow once-daily dosing have been developed, including
Equasym XL®, Ritalin LA®, Metadate CD® and Concerta
XL®. Results from a number of studies have demonstrated
that these long-acting MPH formulations improve the
behavioural and attention-related symptoms of ADHD
over the course of the day [27-31]. In addition, the efficacy
of these formulations has been shown to be comparable
with that of immediate-release MPH, dosed three-times
daily, in a number of double-blind studies [27,29,45].
Consequently, long-acting MPH preparations may have
the potential to improve symptom control beyond the
school day (i.e. extending into the late afternoon and early
evening period), thereby ensuring the optimal personal
development of children with ADHD. Although this sur-
vey found few parent-reported differences between those
children on 6–8 hour medication and those on 12 hour
medication this, as stated earlier, may reflect that the chil-
dren on 12-hour medication were those whose symptoms
were, when untreated, the most severe and long-lasting.
There are several limitations of this survey that must be
noted. Due to the design of the survey, the core selection
criterion for ADHD was based solely on the diagnosis
made by a dedicated healthcare professional. Moreover,
unlike clinical trials in which all attempts are made to
standardise the research setting, surveys are conducted in
the real world under circumstances that can not be fully
controlled. In addition, because the data reported here are
based on parental reports of the impact of their child's
ADHD on everyday activities, general behaviour and fam-
ily relationships, the accuracy of these reports may be sub-
ject to recall bias, subjective reporting by parents and
other types of response errors. In particular, parents may
have been unwilling to indicate whether their child
engaged in behaviours contrary to the generally accepted
norms of society, thereby reducing the reliability and
validity of some of the results. Of note, parental assess-
ment in this survey showed relatively small differences
between medicated and non-mediated children with
ADHD, in terms of the impact of their condition on eve-
ryday activities, general behaviour and family relation-
ships, and the times of day reported by their parents as
challenging. This may be due to the fact that this was an
observational study and that the two ADHD groups (med-
icated and non-medicated ADHD children) were not
matched for severity-of-illness. In addition, no informa-
tion was available on the dosage of medication and med-
ication compliance in the ADHD treatment group.
Concerns regarding the use of stimulation medication for
children with ADHD have been raised across Europe (e.g.
ethical objections of prescribing medication to modify
children's behaviour, lack of evidence for the long-term
effectiveness of stimulant medication and concerns over
the side effects of stimulant medication). This contributes
to wide variations in prescribing practices across Europe.
Consequently, comparisons between medicated and non-
medicated children with ADHD observed in this natural-
istic survey are somewhat difficult to interpret. A further
limitation of this survey is that children with ADHD
receiving the non-stimulant medication Strattera, or who
only received one dose of an immediate-release stimulant
medication, were excluded from the survey, and therefore
the results presented may not generalize to these children.
Overall, this was a large European survey with broad selec-
tion criteria, a factor that should be noted when interpret-
ing the results. In the future, additional studies or surveys
could employ different recruitment strategies and designs
in order that they can provide clearer, accurate and precise
results. In particular, future studies should consider the
validity of the ADHD diagnosis and provide more strin-
gent selection criteria. In addition, analyses designed to
critically evaluate the impact, on the course and outcome
of ADHD, of a range of variables including gender, sever-
ity-of-illness, dosage of medication and/or behavioral
treatment and treatment compliance are required. Such
analyses may help identify and predict which children
with ADHD may respond more optimally to different
treatments. However, despite these limitations, the data
gathered during this parent survey provides clinicians
with a wealth of information on the effect of ADHD and
its medication on the everyday life of affected children
and their families.
Conclusion
Results from this parent survey demonstrates both the
breadth of problems experienced by children with ADHD,
as well as alerting physicians to a range of factors that
should be considered in the management of children with
ADHD. Importantly, by highlighting that children with
ADHD experience challenges throughout the day, with
the afternoon/evening period at least as problematic as
the school day, this survey illustrates the importance of
medication throughout the full active day. To assist both
children with ADHD and their families, such medication
should include a range of behavioural interventions asChild and Adolescent Psychiatry and Mental Health 2008, 2:31 http://www.capmh.com/content/2/1/31
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well as pharmacological treatments that can provide full-
day coverage of symptoms. This will help children with
ADHD achieve their full potential at home and at school,
and with their families and friends. These results also rein-
force the need for good quality medication management
in order to derive maximum benefit from pharmacologi-
cal treatments.
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